# A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer

> **NCT03093272** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 9 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Leuprolide Acetate
- **DRUG:** Prednisone
- **DRUG:** Docetaxel
- **DRUG:** Apalutamide

## Key facts

- **NCT ID:** NCT03093272
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-23
- **Primary completion:** 2019-05-16
- **Final completion:** 2019-12-31
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Safety concerns
- **Last updated:** 2020-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03093272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03093272, "A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT03093272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*